Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress syndrome after surfactant therapy.
Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress syndrome after surfactant therapy.
复制标题
表面活性剂治疗后呼吸窘迫综合征婴儿气管抽吸物中的表面活性剂相关蛋白。
DOI：
10.1164/ajrccm/137.4.943
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
Taeusch,HW
中科院分区：
文献类型：
--
作者：
Chida,S;Phelps,DS;Cordle,C;Soll,R;Floros,J;Taeusch,HW
我们已经开发了酶联免疫测定法（ELISA），测量主要蛋白质，与pUllitaxel表面活性剂。使用这些ELiSA，我们测试了呼吸窘迫综合征（RDS）重症婴儿的连续气管吸出物，这些婴儿在出生后8小时内接受了外源性表面活性剂或安慰剂治疗。平均而言，我们发现在生命的第1天，气管吸出物中的表面活性蛋白浓度较低，随着时间的推移，第三天的凹痕。本研究中使用的表面活性剂（TA表面活性剂）仅含有低分子量（6 kDa）的表面活性剂蛋白而不含35 kDa的表面活性剂蛋白。正如我们所料，与对照组婴儿相比，那些更频繁地使用TA表面活性剂治疗的婴儿在出生后第二天就有可检测到的低分子量表面活性蛋白浓度。到第3天，两组之间的表面活性蛋白浓度没有明显差异，在生命的前3天，两组之间的35 kDa表面活性蛋白浓度也没有明显差异。表面活性剂治疗后1至2天气管抽吸物中的低分子量表面活性剂蛋白增加可能是由于外源性表面活性剂蛋白的持续存在和/或表面活性剂蛋白的产生增加。与其他组RDS患者的测量结果比较证实，这两种表面活性蛋白的缺乏反映了肺泡表面活性物质缺乏。AM修订版DIS 1988; 137：943-947
We have developed enzyme-linked immunoassays (ELISAs) that measure major proteins that are associated with pUlmonary surfactant. Using these ELiSAs, we tested sequential tracheal aspirates from infants severely ill with respiratory distress syndrome (RDS) who had been treated either with exogenous surfactant or with placebo within 8 h of birth. On average, we found low concentrations of surfactant proteins in tracheal aspirates on Day 1 of life, with increases evi-. dent by Day 3. The surfactant used in this stUdy (TA surfactant) contains only the low molecular weight (6 kDa) surfactant proteins and not the 35 kDa surfactant protein. As we expected, those who were treated with TAsurfactant more frequently had detectable concentrations of low molecular weight surfactant protein on the second day of life when compared with control infants. No differences were evident in the concentrations of surfactant proteins between the 2 groups by Day 3, nor were differences evident between the 2 groups evident for 35 kDa surfactant protein during the first 3 days of life. Increased low molecular weight surfactant proteins in tracheal aspirates 1 to 2 days after surfactant therapy may occur either because of persistence of exogenous surfactant proteins and/or enhanced surfactant protein production. Comparisons with measurements from other groups of patients with RDS confirm that absence of both surfactant proteins reflects alveolar surfactant deficiency. AM REV RESPIR DIS 1988; 137: 943-947